Retatrutide vs. Zepbound: Key Differences

Retatrutide and Zepbound Are Not the Same Molecule

Retatrutide and Zepbound are two different compounds at two different stages of development. Zepbound is the brand name for tirzepatide, a drug that received FDA approval for chronic weight management in 2023. Retatrutide is a separate molecule, still in clinical trials, that has not been approved by the FDA for any use. They are often searched together because both are injectable peptides studied for their effects on body weight, and both were developed by Eli Lilly — but a trial drug and an approved prescription product are not interchangeable, and confusing the two leads to confusing claims about what either one does.

How the Two Molecules Work

Both molecules act on the same family of gut-hormone receptors, but they don't act on the same number of them. Tirzepatide is a dual agonist: it activates the GLP-1 receptor and the GIP receptor. Retatrutide adds a third target, the glucagon receptor, making it a triple agonist. Jastreboff et al. (NEJM, 2023) described the phase 2 trial of retatrutide in adults with obesity, reporting body weight outcomes across different dose groups, and the glucagon-receptor component is the mechanistic feature that distinguishes retatrutide's profile from tirzepatide's in that paper.

Tirzepatide's dual-agonist mechanism was characterized earlier in the development program, and its effects in adults with obesity were reported in the SURMOUNT-1 trial (Jastreboff et al., NEJM 2022), the trial that supported the FDA's later decision to approve the molecule as Zepbound for chronic weight management. The receptor count is the structural difference between the two; the clinical and regulatory difference is that one molecule has gone through that approval process and the other has not.

Where Each One Stands With the FDA

Tirzepatide exists as two approved brand products: Mounjaro, approved for type 2 diabetes, and Zepbound, approved in 2023 specifically for chronic weight management (FDA, 2023). Both are manufactured and distributed by Eli Lilly as prescription drugs, with the pen, the labeling, and the regulatory review that status requires.

Retatrutide has no equivalent approval. It is currently in phase 3 trials (Jastreboff et al., NEJM 2026), following earlier phase 2 work in both obesity and type 2 diabetes. A molecule in phase 3 can still fail, succeed, or change in formulation before any regulatory filing is decided. Anyone comparing the two should keep that distinction in view: Zepbound is a finished, approved drug product; retatrutide, at this stage, is a research compound still being studied in controlled trials, and its current catalogue page reflects that status rather than any therapeutic claim.

What PeptoClinic Sells, and What It Doesn't

PeptoClinic does not sell Zepbound, Mounjaro, or any other branded, FDA-approved drug product. What's in the catalog is research material: retatrutide and tirzepatide among the compounds listed, supplied as lyophilized powder for laboratory and research purposes, each lot analyzed by an independent laboratory. The purity standard and the laboratory reports behind it are described on the quality page.

That material is not a substitute for a prescription drug, and ordering it is not a way to obtain Zepbound. The two are different categories: one is a drug product approved after a clinical review by the FDA, the other is a compound still being evaluated in trials, available here as research material with its own catalogue entry and its own price listed on the pricing page.